Merck Buys Sirna Therapeutics
Merck & Co. said Monday that it is acquiring San Francisco-based Sirna Therapeutics, in a transaction worth $1.1B. Sirna Therapeutics develops medicines based on RNA interference (RNAi) technology. Merck will acquire 100 percent of the equity of Sirna for $13 per share in cash. Sirna's RNAi therapeutics are aimed at treating cancer and other conditions. The firm was backed by Oxford Bioscience Partners, Sprout Group, Venrock Associates, and others.
posted on Tuesday, October 31, 2006
Related companies:
Merck
Related stories:
> BioMarin Buys ZyStor Therapeutics
> Iconic Therapeutics Finds $20M
> PEAR Therapeutics Gets $50M For Treating Substance Abuse With Software
> Remedy Informatics Raises $6M
> Arete Therapeutics Raises $35M
silicontap.com Home